Kalogeris, T., Baines, C. P., Krenz, M. & Korthuis, R. J. Ischemia/reperfusion. Compr. Physiol. 7, 113–170 (2016).
Abela, C. B. & Homer-Vanniasinkham, S. Clinical implications of ischaemia-reperfusion injury. Pathophysiology 9, 229–240 (2003).
Bronicki, R. A. & Hall, M. Cardiopulmonary bypass-induced inflammatory response: pathophysiology and treatment. Pediatr. Crit. Care Med. 17, S272–S278 (2016).
Kosieradzki, M. & Rowinski, W. Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant. Proc. 40, 3279–3288 (2008).
Chouchani, E. T. et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 515, 431–435 (2014).
Braunersreuther, V. & Jaquet, V. Reactive oxygen species in myocardial reperfusion injury: from physiopathology to therapeutic approaches. Curr. Pharm. Biotechnol. 13, 97–114 (2012).
Kuznetsov, A. V. et al. The role of mitochondria in the mechanisms of cardiac ischemia-reperfusion injury. Antioxidants (Basel) 8, 454 (2019).
Tang, J. & Zhuang, S. Histone acetylation and DNA methylation in ischemia/reperfusion injury. Clin. Sci. (Lond.) 133, 597–609 (2019).
Tang, J. & Zhuang, S. Epigenetics in acute kidney injury. Curr. Opin. Nephrol. Hypertens. 24, 351–358 (2015).
Tessarz, P. & Kouzarides, T. Histone core modifications regulating nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol. 15, 703–708 (2014).
Ficz, G. New insights into mechanisms that regulate DNA methylation patterning. J. Exp. Biol. 218, 14–20 (2015).
Jonkhout, N. et al. The RNA modification landscape in human disease. RNA 23, 1754–1769 (2017).
Batista, P. J. The RNA Modification N(6)-methyladenosine and Its Implications in Human Disease. Genomics Proteom. Bioinf. 15, 154–163 (2017).
Liu, R. J., Long, T., Li, J., Li, H. & Wang, E. D. Structural basis for substrate binding and catalytic mechanism of a human RNA:m5C methyltransferase NSun6. Nucleic Acids Res. 45, 6684–6697 (2017).
Glasner, H., Riml, C., Micura, R. & Breuker, K. Label-free, direct localization and relative quantitation of the RNA nucleobase methylations m6A, m5C, m3U, and m5U by top-down mass spectrometry. Nucleic Acids Res. 45, 8014–8025 (2017).
Malbec, L. et al. Dynamic methylome of internal mRNA N(7)-methylguanosine and its regulatory role in translation. Cell Res. 29, 927–941 (2019).
Tuck, M. T. The formation of internal 6-methyladenine residues in eucaryotic messenger RNA. Int J. Biochem. 24, 379–386 (1992).
Desrosiers, R., Friderici, K. & Rottman, F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc. Natl. Acad. Sci. USA 71, 3971–3975 (1974).
Yadav, P. K. & Rajasekharan, R. The m(6)A methyltransferase Ime4 and mitochondrial functions in yeast. Curr. Genet. 64, 353–357 (2018).
Yue, H., Nie, X., Yan, Z. & Weining, S. N6-methyladenosine regulatory machinery in plants: composition, function and evolution. Plant Biotechnol. J. 17, 1194–1208 (2019).
Lence, T. et al. m(6)A modulates neuronal functions and sex determination in Drosophila. Nature 540, 242–247 (2016).
Coker, H., Wei, G. & Brockdorff, N. m6A modification of non-coding RNA and the control of mammalian gene expression. Biochim. Biophys. Acta Gene Regul. Mech. 1862, 310–318 (2019).
Erson-Bensan, A. E. & Begik, O. m6A Modification and Implications for microRNAs. MicroRNA 6, 97–101 (2017).
Ma, S. et al. The interplay between m6A RNA methylation and noncoding RNA in cancer. J. Hematol. Oncol. 12, 121 (2019).
Fu, Y., Dominissini, D., Rechavi, G. & He, C. Gene expression regulation mediated through reversible m(6)A RNA methylation. Nat. Rev. Genet 15, 293–306 (2014).
Scholler, E. et al. Interactions, localization, and phosphorylation of the m(6)A generating METTL3-METTL14-WTAP complex. RNA 24, 499–512 (2018).
Liu, J. et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat. Chem. Biol. 10, 93–95 (2014).
Schwartz, S. et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5’ sites. Cell Rep. 8, 284–296 (2014).
Zhao, X. et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Res 24, 1403–1419 (2014).
Fu, Y. et al. FTO-mediated formation of N6-hydroxymethyladenosine and N6-formyladenosine in mammalian RNA. Nat. Commun. 4, 1798 (2013).
Dina, C. et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat. Genet. 39, 724–726 (2007).
Boissel, S. et al. Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations. Am. J. Hum. Genet. 85, 106–111 (2009).
Jia, G. et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol. 7, 885–887 (2011).
Ensfelder, T. T. et al. ALKBH5-induced demethylation of mono- and dimethylated adenosine. Chem. Commun. (Camb.) 54, 8591–8593 (2018).
Zheng, G. et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol. Cell 49, 18–29 (2013).
Zhang, S. et al. m(6)A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell 31, 591–606 e596 (2017).
Zaccara, S., Ries, R. J. & Jaffrey, S. R. Reading, writing and erasing mRNA methylation. Nat. Rev. Mol. Cell Biol. 20, 608–624 (2019).
Berlivet, S., Scutenaire, J., Deragon, J. M. & Bousquet-Antonelli, C. Readers of the m(6)A epitranscriptomic code. Biochim. Biophys. Acta Gene Regul. Mech. 1862, 329–342 (2019).
Liao, S., Sun, H. & Xu, C. YTH domain: a family of N(6)-methyladenosine (m(6)A) readers. Genomics Proteom. Bioinf. 16, 99–107 (2018).
Cienikova, Z., Damberger, F. F., Hall, J., Allain, F. H. & Maris, C. Structural and mechanistic insights into poly(uridine) tract recognition by the hnRNP C RNA recognition motif. J. Am. Chem. Soc. 136, 14536–14544 (2014).
Liu, N. et al. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature 518, 560–564 (2015).
Vilalva, K. H. et al. Use of methylene blue to treat hypovolemic shock followed by ischemia-reperfusion injury in the postoperative orthotopic liver transplant patient: a case report. Exp. Clin. Transplant. 16, 511–514 (2018).
Chies, A. B. et al. Rivastigmine prevents injury induced by ischemia and reperfusion in rat liver. Acta Cir. Bras. 33, 775–784 (2018).
Nakazato, P. C. G. et al. Liver ischemia and reperfusion injury. Pathophysiology and new horizons in preconditioning and therapy. Acta Cir. Bras. 33, 723–735 (2018).
Yao, W. et al. Intravenous anesthetic protects hepatocyte from reactive oxygen species-induced cellular apoptosis during liver transplantation in vivo. Oxid. Med. Cell Longev. 2018, 4780615 (2018).
Wu, H. et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J. Clin. Invest. 117, 2847–2859 (2007).
Koutsogiannidis, C. P. & Johnson, E. O. Pharmacological neuroprotection in cardiac surgery: effectiveness of pharmacologic-preconditioning with erythromycin. Curr. Vasc. Pharm. 16, 329–335 (2018).
de Perrot, M., Liu, M., Waddell, T. K. & Keshavjee, S. Ischemia-reperfusion-induced lung injury. Am. J. Respir. Crit. Care Med. 167, 490–511 (2003).
Eppinger, M. J., Deeb, G. M., Bolling, S. F. & Ward, P. A. Mediators of ischemia-reperfusion injury of rat lung. Am. J. Pathol. 150, 1773–1784 (1997).
Yao, W. et al. Neutrophil elastase inhibitors suppress oxidative stress in lung during liver transplantation. Oxid. Med. Cell Longev. 2019, 7323986 (2019).
Weiser, M. R. et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J. Exp. Med. 183, 2343–2348 (1996).
Menger, M. D., Pelikan, S., Steiner, D. & Messmer, K. Microvascular ischemia-reperfusion injury in striated muscle: significance of “reflow paradox”. Am. J. Physiol. 263, H1901–H1906 (1992).
Junk, A. K. et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA 99, 10659–10664 (2002).
Oharazawa, H. et al. Protection of the retina by rapid diffusion of hydrogen: administration of hydrogen-loaded eye drops in retinal ischemia-reperfusion injury. Invest. Ophthalmol. Vis. Sci. 51, 487–492 (2010).
Oliver, C. N. et al. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc. Natl Acad. Sci. USA 87, 5144–5147 (1990).
Santos, M. R. et al. The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. Clinics 67, 171–178 (2012).
Ciscato, J. G. Jr. et al. Vascular relaxation of canine visceral arteries after ischemia by means of supraceliac aortic cross-clamping followed by reperfusion. Scand. J. Trauma Resusc. Emerg. Med. 18, 41 (2010).
Bertoni, S., Ballabeni, V., Barocelli, E. & Tognolini, M. Mesenteric ischemia-reperfusion: an overview of preclinical drug strategies. Drug Disco. Today 23, 1416–1425 (2018).
Zhao, W. et al. Resveratrol suppresses gut-derived NLRP3 inflammasome partly through stabilizing mast cells in a rat model. Mediators Inflamm. 2018, 6158671 (2018).
Eltzschig, H. K. & Eckle, T. Ischemia and reperfusion–from mechanism to translation. Nat. Med. 17, 1391–1401 (2011).
Yao, W., Tai, L. W., Liu, Y., Hei, Z. & Li, H. Oxidative stress and inflammation interaction in ischemia reperfusion injury: role of programmed cell death. Oxid. Med. Cell Longev. 2019, 6780816 (2019).
Hausenloy, D. J. & Yellon, D. M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc. Res. 61, 448–460 (2004).
Rossello, X. & Yellon, D. M. The RISK pathway and beyond. Basic Res. Cardiol. 113, 2 (2018).
Ghaboura, N. et al. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3beta signaling. Basic Res. Cardiol. 106, 147–162 (2011).
Hausenloy, D. J. & Yellon, D. M. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 12, 217–234 (2007).
Hadebe, N., Cour, M. & Lecour, S. The SAFE pathway for cardioprotection: is this a promising target? Basic Res. Cardiol. 113, 9 (2018).
Lecour, S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J. Mol. Cell Cardiol. 47, 32–40 (2009).
Lecour, S. & James, R. W. When are pro-inflammatory cytokines SAFE in heart failure? Eur. Heart J. 32, 680–685 (2011).
Inserte, J. & Garcia-Dorado, D. The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism. Br. J. Pharm. 172, 1996–2009 (2015).
Cohen, M. V., Yang, X. M., Liu, Y., Solenkova, N. V. & Downey, J. M. Cardioprotective PKG-independent NO signaling at reperfusion. Am. J. Physiol. Heart Circ. Physiol. 299, H2028–H2036 (2010).
Hsu, H. H. et al. Protection against reperfusion lung injury via aborgating multiple signaling cascades by trichostatin A. Int. Immunopharmacol. 25, 267–275 (2015).
Evankovich, J. et al. High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J. Biol. Chem. 285, 39888–39897 (2010).
Kim, K. et al. Effect of valproic acid on acute lung injury in a rodent model of intestinal ischemia reperfusion. Resuscitation 83, 243–248 (2012).
Guo, Y. et al. Trichostatin A attenuates oxidative stress-mediated myocardial injury through the FoxO3a signaling pathway. Int. J. Mol. Med 40, 999–1008 (2017).
Huang, N., Tan, L., Xue, Z., Cang, J. & Wang, H. Reduction of DNA hydroxymethylation in the mouse kidney insulted by ischemia reperfusion. Biochem. Biophys. Res. Commun. 422, 697–702 (2012).
Tampe, B. et al. Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression. Kidney Int. 91, 157–176 (2017).
Li, J. et al. Genome-wide analysis of DNA methylation and acute coronary syndrome. Circ. Res. 120, 1754–1767 (2017).
Li, D. et al. Genome-wide DNA methylome alterations in acute coronary syndrome. Int J. Mol. Med. 41, 220–232 (2018).
Ke, J. et al. Role of DNA methylation in perinatal nicotine-induced development of heart ischemia-sensitive phenotype in rat offspring. Oncotarget 8, 76865–76880 (2017).
Endres, M. et al. DNA methyltransferase contributes to delayed ischemic brain injury. J. Neurosci. 20, 3175–3181 (2000).
Li, Q. et al. NSUN2-mediated m5C methylation and METTL3/METTL14-mediated m6A methylation cooperatively enhance p21 translation. J. Cell Biochem. 118, 2587–2598 (2017).
Anders, M. et al. Dynamic m(6)A methylation facilitates mRNA triaging to stress granules. Life Sci. Alliance 1, e201800113 (2018).
Zhong, X. et al. Circadian clock regulation of hepatic lpid metabolism by modulation of m(6)A mRNA methylation. Cell Rep. 25, 1816–1828 e1814 (2018).
Fry, N. J., Law, B. A., Ilkayeva, O. R., Holley, C. L. & Mansfield, K. D. N(6)-methyladenosine is required for the hypoxic stabilization of specific mRNAs. RNA 23, 1444–1455 (2017).
Wu, L. et al. Association of N(6)-methyladenine DNA with plaque progression in atherosclerosis via myocardial infarction-associated transcripts. Cell Death Dis. 10, 909 (2019).
Dorn, L. E. et al. The N(6)-methyladenosine mRNA methylase METTL3 controls cardiac homeostasis and hypertrophy. Circulation 139, 533–545 (2019).
Song, H. et al. METTL3 and ALKBH5 oppositely regulate m(6)A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes. Autophagy 15, 1419–1437 (2019).
Shen, F. et al. Decreased N(6)-methyladenosine in peripheral blood RNA from diabetic patients is associated with FTO expression rather than ALKBH5. J. Clin. Endocrinol. Metab. 100, E148–E154 (2015).
Mathiyalagan, P. et al. FTO-dependent N(6)-methyladenosine regulates cardiac function during remodeling and repair. Circulation 139, 518–532 (2019).
Wang, X. et al. FTO is required for myogenesis by positively regulating mTOR-PGC-1alpha pathway-mediated mitochondria biogenesis. Cell Death Dis. 8, e2702 (2017).
Xuan, Z. et al. Dexmedetomidine postconditioning alleviates hypoxia/reoxygenation injury in senescent myocardial cells by regulating lncRNA H19 and m6A modification. Oxid. Med. Cell Longev. 2020, 9250512 (2020).
Saxena, R., Weintraub, N. L. & Tang, Y. Optimizing cardiac ischemic preconditioning and postconditioning via epitranscriptional regulation. Med. Hypotheses 135, 109451 (2020).
Leng, T., Shi, Y., Xiong, Z. G. & Sun, D. Proton-sensitive cation channels and ion exchangers in ischemic brain injury: new therapeutic targets for stroke? Prog. Neurobiol. 115, 189–209 (2014).
Galkin, A. Brain ischemia/reperfusion injury and mitochondrial complex I damage. Biochemistry 84, 1411–1423 (2019).
Xin, Q. et al. Endoplasmic reticulum stress in cerebral ischemia. Neurochem. Int. 68, 18–27 (2014).
Liu, J. et al. Neuronal apoptosis in cerebral ischemia/reperfusion area following electrical stimulation of fastigial nucleus. Neural Regen. Res 9, 727–734 (2014).
Yang, Q., Huang, Q., Hu, Z. & Tang, X. Potential neuroprotective treatment of stroke: targeting excitotoxicity, oxidative stress, and inflammation. Front. Neurosci. 13, 1036 (2019).
DeGracia, D. J. Disease of mRNA regulation: relevance for ischemic brain injury. Transl. Stroke Res. 9, 251–257 (2018).
Chen, Y. & Zhou, J. LncRNAs: macromolecules with big roles in neurobiology and neurological diseases. Metab. Brain Dis. 32, 281–291 (2017).
Yang, J., Chen, M., Cao, R. Y., Li, Q. & Zhu, F. The role of circular RNAs in cerebral ischemic diseases: ischemic stroke and cerebral ischemia/reperfusion injury. Adv. Exp. Med. Biol. 1087, 309–325 (2018).
Hess, M. E. et al. The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry. Nat. Neurosci. 16, 1042–1048 (2013).
Widagdo, J. & Anggono, V. The m6A-epitranscriptomic signature in neurobiology: from neurodevelopment to brain plasticity. J. Neurochem. 147, 137–152 (2018).
Chokkalla, A. K. et al. Transient focal ischemia significantly alters the m(6)A epitranscriptomic tagging of RNAs in the brain. Stroke 50, 2912–2921 (2019).
Diao, M. Y. et al. Hypothermia protects neurons against ischemia/reperfusion-induced pyroptosis via m6A-mediated activation of PTEN and the PI3K/Akt/GSK-3beta signaling pathway. Brain Res. Bull. 159, 25–31 (2020).
Malek, M. & Nematbakhsh, M. Renal ischemia/reperfusion injury; from pathophysiology to treatment. J. Ren. Inj. Prev. 4, 20–27 (2015).
Chen, C. et al. Crosstalk between connexin32 and mitochondrial apoptotic signaling pathway plays a pivotal role in renal ischemia reperfusion-induced acute kidney injury. Antioxid. Redox Signal. 30, 1521–1538 (2018).
Zhuang, C. et al. N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1alpha signalling axis. J. Cell Mol. Med. 23, 2163–2173 (2019).
Fiorentino, M., Grandaliano, G., Gesualdo, L. & Castellano, G. Acute kidney injury to chronic kidney disease transition. Contrib. Nephrol. 193, 45–54 (2018).
Xu, Y. et al. The N6-methyladenosine mRNA methylase METTL14 promotes renal ischemic reperfusion injury via suppressing YAP1. J. Cell Biochem. 121, 524–533 (2020).
Aschenbrenner, J. et al. Engineering of a DNA polymerase for direct m(6) A sequencing. Angew. Chem. Int. Ed. Engl. 57, 417–421 (2018).
Garalde, D. R. et al. Highly parallel direct RNA sequencing on an array of nanopores. Nat. Methods 15, 201–206 (2018).
Francis, A. & Baynosa, R. Ischaemia-reperfusion injury and hyperbaric oxygen pathways: a review of cellular mechanisms. Diving Hyperb. Med. 47, 110–117 (2017).
Pak, S. et al. Platelet adhesion in the sinusoid caused hepatic injury by neutrophils after hepatic ischemia reperfusion. Platelets 21, 282–288 (2010).
Kalogeris, T., Baines, C. P., Krenz, M. & Korthuis, R. J. Cell biology of ischemia/reperfusion injury. Int. Rev. Cell Mol. Biol. 298, 229–317 (2012).